BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32083303)

  • 1. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
    Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
    Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Duruisseaux M; Antoine M; Rabbe N; Rodenas A; Mc Leer-Florin A; Lacave R; Poulot V; Duchêne B; Van Seuningen I; Cadranel J; Wislez M
    Lung Cancer; 2017 Jul; 109():92-100. PubMed ID: 28577958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
    Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma.
    Kishikawa S; Hayashi T; Saito T; Takamochi K; Kohsaka S; Sano K; Sasahara N; Sasa K; Kurihara T; Hara K; Suehara Y; Takahashi F; Suzuki K; Yao T
    Mod Pathol; 2021 Apr; 34(4):786-797. PubMed ID: 33024306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
    Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
    World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.
    Bauer AK; Umer M; Richardson VL; Cumpian AM; Harder AQ; Khosravi N; Azzegagh Z; Hara NM; Ehre C; Mohebnasab M; Caetano MS; Merrick DT; van Bokhoven A; Wistuba II; Kadara H; Dickey BF; Velmurugan K; Mann PR; Lu X; Barón AE; Evans CM; Moghaddam SJ
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer.
    Lee HK; Kwon MJ; Seo J; Kim JW; Hong M; Park HR; Min SK; Choe JY; Ra YJ; Jang SH; Hwang YI; Kim HY; Min KW
    Pathol Res Pract; 2019 Mar; 215(3):459-465. PubMed ID: 30580903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma.
    Wakejima R; Inamura K; Ninomiya H; Nagano H; Mun M; Okumura S; Okubo K; Ishikawa Y
    Pathol Int; 2020 Feb; 70(2):72-83. PubMed ID: 31859434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4α expression, and KRAS mutations.
    Nakajima N; Yoshizawa A; Nakajima T; Hirata M; Furuhata A; Sumiyoshi S; Rokutan-Kurata M; Sonobe M; Menju T; Miyamoto E; Chen-Yoshikawa TF; Date H; Haga H
    Histopathology; 2018 Jul; 73(1):38-48. PubMed ID: 29469192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma.
    Imai Y; Yamagishi H; Fukuda K; Ono Y; Inoue T; Ueda Y
    World J Gastroenterol; 2013 Jul; 19(25):3957-68. PubMed ID: 23840140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
    Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
    Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
    Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
    Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of lung adenocarcinoma with KRAS mutations.
    Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I
    Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.
    Qu Y; Zhao D; Mu J; Che N; Zhang C; Liu Z; Su D; Zhou L; Zhang H; Wei L
    Tumour Biol; 2016 Jan; 37(1):887-96. PubMed ID: 26254613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.